Feed RCUS
RC

Arcus Biosciences, Inc.

RCUS · NYSE

$24.08 -2.05% (-$0.51)
1M -18.57%
Market Cap $3.03B
P/E Ratio -
Div. Yield -
ROE 87.98%

Bulios Fair Price

$28.99

20.4% upside

Preț actual

$24.08

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile RCUS sunt în prezent subevaluate față de prețul lor de piață. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Weak
0/9
Valuation
9 /100
Expensive
P/S 25.89x
P/B 6.53x
P/E N/A
Growth
82 /100
Growing
Rev. growth 30.16%
Book val. growth 1.34%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 94.02%
Net margin 386.33%
Op. margin 415.39%
Quality
2 /100
Poor
ROIC 65.76%
ROE 87.98%
ROA 48.92%
Debt
69 /100
Low
Debt/Equity 0.25x
Current ratio 3.82x
Int. coverage -18.65x
Stability
53 /100
Moderate
Beta 0.81x
Rev. volatility 69.66%
EPS volatility 19.18%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre RCUS
Online

Despre companie

Arcus Biosciences, Inc. (RCUS) is an American biotechnology company focused on researching and developing new drugs for the treatment of oncology and inflammatory diseases. The company specializes in discovering innovative therapeutic drugs based on immunotherapy and cell growth pathway inhibition. Its research and development efforts are aimed at boosting the immune system's ability to fight against cancer cells and inflammatory processes. Arcus Biosciences collaborates with pharmaceutical companies and academic institutions in the discovery and development of new drugs and therapies. The company aims to bring innovative treatment options to patients facing challenging and difficult-to-treat diseases. Arcus Biosciences, Inc. is recognized for its research potential and influential position in the field of immuno-oncology. Arcus Biosciences, Inc. (RCUS) shares may represent an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with an innovative portfolio of research in oncology and immunotherapy.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Terry J. Rosen

Employees

601

Headquarters

Hayward

Evenimente viitoare

27 OCT.

Earnings

Upcoming earnings report

42d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.